Chronic Obstructive Pulmonary Disease (COPD)NCT07757126
Lung Ultrasound With Acute Exacerbation and Stable COPD
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
This cross-sectional study aims to compare lung ultrasound findings, functional capacity, and dyspnea among patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), patients with stable COPD, and healthy controls. Read more about this study
- Who is it for?
- Ages 40 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD)
- How many people
- 85 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 18 May 2026to 30 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults aged 40-75 years will be recruited from Munzur University and Tunceli State Hospital. The study population will consist of three groups: patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), patients with clinically stable COPD, and age-matched healthy controls. Eligible participants will be enrolled consecutively after providing written informed consent and will undergo standardized assessments, including lung ultrasound, pulmonary function testing, functional capacity tests, dyspnea evaluation, and psychological assessments.
Who may be able to join
- Acute Exacerbation COPD Group
- Adults aged 40-65 years.
- Diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD criteria.
- Currently experiencing an acute exacerbation of COPD.
- Able and willing to provide written informed consent.
- Stable COPD Group
Show all 14Show fewer
- Adults aged 40-75 years.
- Diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD criteria.
- Clinically stable without an acute exacerbation at the time of assessment.
- Able and willing to provide written informed consent.
- Healthy Control Group
- Adults aged 40-65 years.
- No history of chronic pulmonary disease.
- Able and willing to provide written informed consent.
Who cannot join
- Presence of cardiovascular, neurological, orthopedic, psychiatric, or other systemic diseases that may affect study assessments.
- Cognitive impairment or psychological conditions preventing completion of study procedures.
- History of thoracic or major surgery that could influence pulmonary function or lung ultrasound findings.
- Pregnancy.
- Inability to perform pulmonary function testing or functional exercise tests.
- Refusal or inability to provide written informed consent.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Munzur University Faculty of Health Sciences
Tunceli
About this study
Official title: Comparison of Lung Ultrasound Findings, Functional Capacity, and Dyspnea Between Patients With Acute Exacerbation and Stable Chronic Obstructive Pulmonary Disease
This cross-sectional study aims to compare lung ultrasound findings, functional capacity, and dyspnea among patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), patients with stable COPD, and healthy controls. The study will include approximately 60 participants divided into three groups (acute exacerbation COPD, stable COPD, and healthy controls). Participants will undergo comprehensive assessments including lung ultrasound, pulmonary function tests, the Modified Borg Scale, the Modified Medical Research Council (mMRC) Dyspnea Scale, the 6-Minute Walk Test, the 1-Minute Sit-to-Stand Test, the COPD Assessment Test (CAT), the Charlson Comorbidity Index, and the BODE Index. The primary objective is to determine differences in lung ultrasound abnormalities, particularly B-lines, consolidations, and lung ultrasound scores, and to investigate their relationship with functional capacity and dyspnea severity. The findings are expected to clarify the clinical utility of lung ultrasound as a non-invasive bedside assessment tool for evaluating disease severity and supporting comprehensive management of patients with COPD.
Read the detailed description
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation, chronic respiratory symptoms, and recurrent exacerbations that contribute to substantial morbidity, mortality, and healthcare utilization. Acute exacerbations accelerate disease progression, impair functional capacity, increase dyspnea severity, and worsen quality of life. Early identification of pulmonary abnormalities during exacerbation is therefore essential for optimizing clinical management and improving patient outcomes.
Lung ultrasound (LUS) has emerged as a non-invasive, radiation-free, bedside imaging modality that enables rapid assessment of pulmonary pathology. LUS can identify clinically relevant findings such as B-lines, consolidations, pleural abnormalities, and pleural effusions, making it a valuable complementary tool in the evaluation of respiratory diseases. Because it is portable, repeatable, and safe, LUS is increasingly incorporated into the assessment and monitoring of patients with chronic respiratory disorders, including COPD. Despite these advantages, evidence regarding the role of lung ultrasound in distinguishing acute exacerbation from stable COPD and its relationship with clinical outcomes remains limited.
The present study is designed as a cross-sectional comparative study involving three groups: patients with acute exacerbation of COPD, patients with stable COPD, and healthy individuals. Approximately 60 participants will be recruited and undergo standardized assessments. Lung ultrasound will be performed using a 12-zone protocol to evaluate B-line distribution, A-line dominance, lung ultrasound score, consolidations, pleural effusion, and other sonographic abnormalities. Functional status and symptom burden will be assessed using the 6-Minute Walk Test (6MWT), 1-Minute Sit-to-Stand Test (1STS), Modified Borg Dyspnea Scale, modified Medical Research Council (mMRC) Dyspnea Scale, COPD Assessment Test (CAT), Charlson Comorbidity Index, BODE Index, and spirometry.
The primary objective of this study is to compare lung ultrasound findings, functional capacity, and dyspnea among patients with acute exacerbation COPD, stable COPD, and healthy controls. Additionally, the study aims to determine whether lung ultrasound findings are associated with functional impairment and symptom severity. The results are expected to provide evidence supporting the clinical utility of lung ultrasound as a rapid and comprehensive assessment tool that complements conventional clinical evaluation in COPD and contributes to multidisciplinary management strategies.
- Keywords
- Chronic Obstructive Pulmonary Disease (COPD), Acute Exacerbation, Lung Ultrasound, Functional Capacity, Dyspnea
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Dyspnea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Acute Exacerbation COPD | Patients diagnosed with chronic obstructive pulmonary disease (COPD) who are experiencing an acute exacerbation. Participants will undergo lung ultrasound, pulmonary function testing, functional capacity assessment (6-Minute Walk Test and 1-Minute Sit-to-Stand Test), dyspnea evaluation (Modified Borg Scale and mMRC Dyspnea Scale), COPD Assessment Test (CAT), Charlson Comorbidity Index, and BODE Index. | |
| Stable COPD | Patients with clinically stable chronic obstructive pulmonary disease (COPD) without an acute exacerbation. Participants will undergo the same assessments as the acute exacerbation group, including lung ultrasound, pulmonary function testing, functional capacity tests, dyspnea evaluation, CAT, Charlson Comorbidity Index, and BODE Index. | |
| Healthy Controls | Age-matched healthy individuals without chronic pulmonary disease or other significant cardiopulmonary, neurological, orthopedic, or psychiatric disorders. Participants will undergo lung ultrasound, pulmonary function testing, functional capacity assessment, and dyspnea evaluation using the same standardized procedures as the COPD groups. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lung Ultrasound Score
Total lung ultrasound score (0-36) obtained using a standardized 12-zone lung ultrasound protocol. The score reflects the degree of lung aeration loss based on the presence of A-lines, B-lines, confluent B-lines, and consolidations.
Measured: Baseline (Cross-sectional assessment)
Secondary outcomes (16)
Six-Minute Walk Distance (6MWD)
Functional exercise capacity assessed using the Six-Minute Walk Test according to American Thoracic Society (ATS) guidelines. The outcome is the total distance walked in six minutes, measured in meters (m). Higher walking distances indicate better functional exercise capacity. Although there is no fixed maximum distance, the practical measurement range extends from 0 m upward.
Measured: Baseline
One-Minute Sit-to-Stand Test
Functional capacity assessed by the total number of sit-to-stand repetitions completed in one minute.
Measured: Baseline
Modified Borg Dyspnea Scale
Perceived dyspnea intensity at rest and immediately after exercise assessed using the Modified Borg Dyspnea Scale. The Modified Borg Dyspnea Scale ranges from 0 to 10, where 0 indicates no breathlessness and 10 indicates maximal breathlessness. Lower scores indicate less dyspnea (better outcome), whereas higher scores indicate greater dyspnea (worse outcome).
Measured: Baseline
Modified Medical Research Council (mMRC) Dyspnea Scale
Dyspnea severity during daily activities assessed using the Modified Medical Research Council Dyspnea Scale. The Modified Medical Research Council Dyspnea Scale ranges from 0 to 4, where 0 indicates breathlessness only with strenuous exercise and 4 indicates severe breathlessness that prevents leaving the house or occurs during dressing or undressing. Lower scores indicate less dyspnea (better outcome), whereas higher scores indicate greater dyspnea severity (worse outcome).
Measured: Baseline
COPD Assessment Test (CAT)
COPD symptom burden and health status assessed using the Chronic Obstructive Pulmonary Disease Assessment Test. The Chronic Obstructive Pulmonary Disease Assessment Test consists of 8 items and ranges from 0 to 40, where 0 indicates no impact of COPD on health status and 40 indicates maximum impact. Lower scores indicate better health status and lower symptom burden (better outcome), whereas higher scores indicate worse health status and greater symptom burden (worse outcome).
Measured: Baseline
BODE Index
Disease severity and mortality risk assessed using the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index. The BODE Index ranges from 0 to 10, where 0 indicates the lowest disease severity and mortality risk and 10 indicates the highest disease severity and mortality risk. Lower scores indicate better clinical status and prognosis (better outcome), whereas higher scores indicate worse clinical status and increased mortality risk (worse outcome).
Measured: Baseline
Charlson Comorbidity Index
Comorbidity burden assessed using the Charlson Comorbidity Index. The Charlson Comorbidity Index ranges from 0 upward, with higher scores indicating a greater burden of comorbidity and an increased risk of mortality. A score of 0 indicates no comorbid conditions. Lower scores indicate a lower comorbidity burden (better outcome), whereas higher scores indicate a greater comorbidity burden (worse outcome).
Measured: Baseline
Depression Anxiety Stress Scale-21 - Depression Subscale
Depressive symptoms assessed using the Depression Anxiety Stress Scale-21 Depression Subscale. The Depression Anxiety Stress Scale-21 Depression Subscale ranges from 0 to 42, with higher scores indicating greater depressive symptom severity. Lower scores indicate fewer depressive symptoms (better outcome), whereas higher scores indicate more severe depressive symptoms (worse outcome).
Measured: Baseline
Depression Anxiety Stress Scale-21 - Stress Subscale
Stress symptoms assessed using the Depression Anxiety Stress Scale-21 Stress Subscale. The Depression Anxiety Stress Scale-21 Stress Subscale ranges from 0 to 42, with higher scores indicating greater stress symptom severity. Lower scores indicate fewer stress symptoms (better outcome), whereas higher scores indicate more severe stress symptoms (worse outcome).
Measured: Baseline
Depression Anxiety Stress Scale-21 - Anxiety Subscale
Anxiety symptoms assessed using the Depression Anxiety Stress Scale-21 Anxiety Subscale. The Depression Anxiety Stress Scale-21 Anxiety Subscale ranges from 0 to 42, with higher scores indicating greater anxiety symptom severity. Lower scores indicate fewer anxiety symptoms (better outcome), whereas higher scores indicate more severe anxiety symptoms (worse outcome).
Measured: Baseline
Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Anxiety symptoms assessed using the Hospital Anxiety and Depression Scale-Anxiety Subscale. The Hospital Anxiety and Depression Scale-Anxiety Subscale ranges from 0 to 21, where higher scores indicate greater anxiety severity. Lower scores indicate less anxiety (better outcome), whereas higher scores indicate more severe anxiety symptoms (worse outcome).
Measured: Baseline
Hospital Anxiety and Depression Scale - Depression Subscale (HADS-D)
Depressive symptoms assessed using the Hospital Anxiety and Depression Scale-Depression Subscale. The Hospital Anxiety and Depression Scale-Depression Subscale ranges from 0 to 21, where higher scores indicate greater depression severity. Lower scores indicate fewer depressive symptoms (better outcome), whereas higher scores indicate more severe depressive symptoms (worse outcome).
Measured: Baseline
Forced Expiratory Volume in One Second (FEV1)
Pulmonary function assessed by spirometry. Forced Expiratory Volume in One Second (FEV1) expressed as percent predicted (%) based on reference values. Higher values indicate better pulmonary function.
Measured: Baseline
Forced Vital Capacity (FVC)
Pulmonary function assessed by spirometry. Forced Vital Capacity (FVC) expressed as percent predicted (%) based on reference values. Higher values indicate better pulmonary function.
Measured: Baseline
Peak Expiratory Flow (PEF)
Pulmonary function assessed by spirometry. Peak Expiratory Flow (PEF) expressed as percent predicted (%) based on reference values. Higher values indicate better pulmonary function.
Measured: Baseline
Forced Expiratory Flow at 25-75% of Forced Vital Capacity (FEF25-75%)
Pulmonary function assessed by spirometry. Forced Expiratory Flow at 25-75% of Forced Vital Capacity (FEF25-75%) expressed as percent predicted (%) based on reference values. Higher values indicate better pulmonary function.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2026
- Study start18 May 2026
- Primary completion20 Jul 2026
- Study completion30 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 85 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ceyhun Topcuoglu, Munzur University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07757126
- Sponsor's protocol ID
- 2026/7-14
- Status last verified
- Aug 2026
- First submitted
- 2 Aug 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012 Apr;38(4):577-91. doi: 10.1007/s00134-012-2513-4. Epub 2012 Mar 6.
PubMed 22392031
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Lung Ultrasound Findings, Functional Capacity, and Dyspnea Between Patients With Acute Exacerbation and Stable Chronic Obstructive Pulmonary Disease
- ClinicalTrials.gov ID
- NCT07757126
- Acronym / sponsor ID
- 2026/7-14
- Keywords
- Chronic Obstructive Pulmonary Disease (COPD), Acute Exacerbation, Lung Ultrasound, Functional Capacity, Dyspnea
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 85 participants (actual)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 18 May 2026 (actual)
- Primary completion
- 20 Jul 2026 (actual)
- Study completion
- 30 Jul 2026 (actual)
- First posted
- 11 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to compare lung ultrasound findings, functional capacity, and dyspnea among patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), patients with stable COPD, and healthy controls. The study will include approximately 60 participants divided into three groups (acute exacerbation COPD, stable COPD, and healthy controls). Participants will undergo comprehensive assessments including lung ultrasound, pulmonary function tests, the Modified Borg Scale, the Modified Medical Research Council (mMRC) Dyspnea Scale, the 6-Minute Walk Test, the 1-Minute Sit-to-Stand Test, the COPD Assessment Test (CAT), the Charlson Comorbidity Index, and the BODE Index. The primary objective is to determine differences in lung ultrasound abnormalities, particularly B-lines, consolidations, and lung ultrasound scores, and to investigate their relationship with functional capacity and dyspnea severity. The findings are expected to clarify the clinical utility of lung ultrasound as a non-invasive bedside assessment tool for evaluating disease severity and supporting comprehensive management of patients with COPD.
Detailed description
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation, chronic respiratory symptoms, and recurrent exacerbations that contribute to substantial morbidity, mortality, and healthcare utilization. Acute exacerbations accelerate disease progression, impair functional capacity, increase dyspnea severity, and worsen quality of life. Early identification of pulmonary abnormalities during exacerbation is therefore essential for optimizing clinical management and improving patient outcomes.
Lung ultrasound (LUS) has emerged as a non-invasive, radiation-free, bedside imaging modality that enables rapid assessment of pulmonary pathology. LUS can identify clinically relevant findings such as B-lines, consolidations, pleural abnormalities, and pleural effusions, making it a valuable complementary tool in the evaluation of respiratory diseases. Because it is portable, repeatable, and safe, LUS is increasingly incorporated into the assessment and monitoring of patients with chronic respiratory disorders, including COPD. Despite these advantages, evidence regarding the role of lung ultrasound in distinguishing acute exacerbation from stable COPD and its relationship with clinical outcomes remains limited.
The present study is designed as a cross-sectional comparative study involving three groups: patients with acute exacerbation of COPD, patients with stable COPD, and healthy individuals. Approximately 60 participants will be recruited and undergo standardized assessments. Lung ultrasound will be performed using a 12-zone protocol to evaluate B-line distribution, A-line dominance, lung ultrasound score, consolidations, pleural effusion, and other sonographic abnormalities. Functional status and symptom burden will be assessed using the 6-Minute Walk Test (6MWT), 1-Minute Sit-to-Stand Test (1STS), Modified Borg Dyspnea Scale, modified Medical Research Council (mMRC) Dyspnea Scale, COPD Assessment Test (CAT), Charlson Comorbidity Index, BODE Index, and spirometry.
The primary objective of this study is to compare lung ultrasound findings, functional capacity, and dyspnea among patients with acute exacerbation COPD, stable COPD, and healthy controls. Additionally, the study aims to determine whether lung ultrasound findings are associated with functional impairment and symptom severity. The results are expected to provide evidence supporting the clinical utility of lung ultrasound as a rapid and comprehensive assessment tool that complements conventional clinical evaluation in COPD and contributes to multidisciplinary management strategies.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Acute Exacerbation COPD | – | –Patients diagnosed with chronic obstructive pulmonary disease (COPD) who are experiencing an acute exacerbation. Participants will undergo lung ultrasound, pulmonary function testing, functional capacity assessment (6-Minute Walk Test and 1-Minute Sit-to-Stand Test), dyspnea evaluation (Modified Borg Scale and mMRC Dyspnea Scale), COPD Assessment Test (CAT), Charlson Comorbidity Index, and BODE Index. |
| Stable COPD | – | –Patients with clinically stable chronic obstructive pulmonary disease (COPD) without an acute exacerbation. Participants will undergo the same assessments as the acute exacerbation group, including lung ultrasound, pulmonary function testing, functional capacity tests, dyspnea evaluation, CAT, Charlson Comorbidity Index, and BODE Index. |
| Healthy Controls | – | –Age-matched healthy individuals without chronic pulmonary disease or other significant cardiopulmonary, neurological, orthopedic, or psychiatric disorders. Participants will undergo lung ultrasound, pulmonary function testing, functional capacity assessment, and dyspnea evaluation using the same standardized procedures as the COPD groups. |
Who may qualify
- Ages
- 40 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 40-75 years will be recruited from Munzur University and Tunceli State Hospital. The study population will consist of three groups: patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), patients with clinically stable COPD, and age-matched healthy controls. Eligible participants will be enrolled consecutively after providing written informed consent and will undergo standardized assessments, including lung ultrasound, pulmonary function testing, functional capacity tests, dyspnea evaluation, and psychological assessments.
Key inclusion criteria (14 listed)
- Acute Exacerbation COPD Group
- Stable COPD Group
- Healthy Control Group
Key exclusion criteria (6 listed)
- Presence of cardiovascular, neurological, orthopedic, psychiatric, or other systemic diseases that may affect study assessments.
- Cognitive impairment or psychological conditions preventing completion of study procedures.
- History of thoracic or major surgery that could influence pulmonary function or lung ultrasound findings.
- Pregnancy.
- Inability to perform pulmonary function testing or functional exercise tests.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Lung Ultrasound Score
Time frame: Baseline (Cross-sectional assessment)
Total lung ultrasound score (0-36) obtained using a standardized 12-zone lung ultrasound protocol. The score reflects the degree of lung aeration loss based on the presence of A-lines, B-lines, confluent B-lines, and consolidations.
16 secondary outcomes
Six-Minute Walk Distance (6MWD)
Time frame: Baseline
One-Minute Sit-to-Stand Test
Time frame: Baseline
Modified Borg Dyspnea Scale
Time frame: Baseline
Modified Medical Research Council (mMRC) Dyspnea Scale
Time frame: Baseline
COPD Assessment Test (CAT)
Time frame: Baseline
BODE Index
Time frame: Baseline
Charlson Comorbidity Index
Time frame: Baseline
Depression Anxiety Stress Scale-21 - Depression Subscale
Time frame: Baseline
Depression Anxiety Stress Scale-21 - Stress Subscale
Time frame: Baseline
Depression Anxiety Stress Scale-21 - Anxiety Subscale
Time frame: Baseline
Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Time frame: Baseline
Hospital Anxiety and Depression Scale - Depression Subscale (HADS-D)
Time frame: Baseline
Forced Expiratory Volume in One Second (FEV1)
Time frame: Baseline
Forced Vital Capacity (FVC)
Time frame: Baseline
Peak Expiratory Flow (PEF)
Time frame: Baseline
Forced Expiratory Flow at 25-75% of Forced Vital Capacity (FEF25-75%)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Background: PubMed 22392031Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012 Apr;38(4):577-91. doi: 10.1007/s00134-012-2513-4. Epub 2012 Mar 6.
- Individual participant dataSharing planned: No
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lung Ultrasound Score (time frame: Baseline (Cross-sectional assessment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07757126, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.